Meeting with far-reaching consequences: chemie.de brings together start-up and established company

New development on show for the first time at analytica

22-Mar-2024 - In the dynamic world of start-ups, a chance encounter can have unexpected and far-reaching consequences. A perfect example of this dynamic is the story of the cooperation between the start-up droptical and the company DataPhysics Instruments, which began at an event organized by BayStartUp and ...

Personalize your medication dosages

Initial clinical tests show that biosensors could pave the way for a personalized antibiotherapy in the future

18-Jul-2017 - Personalized drug therapy, adjusting the dose, dosage intervals, and the duration of treatment to fit individual patients' needs, are getting more and more important. Frequently, medications are dosed in such a way that each patient receives the same standardized amount of a certain drug. ...

Adding genetics to a patient's clinical profile might lead to more accurate blood-thinner dosing

23-Feb-2009 - Including genetic information in a patient's clinical profile might help determine the optimal starting dose of the common blood-thinner warfarin, according to findings from a large-scale study that will be published in the New England Journal of Medicine. Researchers from more than 20 ...

Corcept Therapeutics and Xceleron sign agreement for microdosing study using accelerator mass spectrometry

27-Jul-2007 - Corcept Therapeutics and Xceleron announced an agreement for a human microdosing study of one of Corcept's new chemical entities, a selective GR-II antagonist, utilizing Xceleron's Accelerator Mass Spectrometry (AMS) technology. In early 2003, Corcept initiated a discovery research program to ...

New Drug Delivery Techniques Aim to Improve Overall Drug Performance and Efficacy

15-Mar-2005 - Quantum leaps made in the field of proteomics, genomics and biotechnology are creating revolutionary therapeutics that require equally impressive drug delivery systems in order for patients to derive optimum benefits. This, coupled with patent expirations and subsequent competitive threats from ...

Roche's AmpliChip CYP450 Test receives FDA clearance

First microarray-based diagnostic test for detection of genetic variations that can influence drug efficacy and adverse drug reactions

24-Feb-2005 - Roche announced that its first microarray-based test, the AmpliChip CYP450 Test, has been cleared by the US Food and Drug Administration (FDA) for diagnostic use in the United States. This test, which is powered by Affymetrix microarray technology, analyses a patient's Cytochrome P450 2D6 and ...